Brand Name

Vyzulta

Generic Name
Latanoprostene Bunod
View Brand Information
FDA approval date: November 02, 2017
Form: Solution

What is Vyzulta (Latanoprostene Bunod)?

VYZULTA ®

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Soluble Guanylate Cyclase Modulators in Glaucoma and Ocular Fibrosis: Mechanisms, Translational Evidence, and Therapeutic Challenges.
Soluble Guanylate Cyclase Modulators in Glaucoma and Ocular Fibrosis: Mechanisms, Translational Evidence, and Therapeutic Challenges.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Published: June 12, 2026
A Comprehensive Review of the Clinical Evidence Comparing Benzalkonium Chloride-Preserved and Benzalkonium Chloride-Free Latanoprost in the Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension.
A Comprehensive Review of the Clinical Evidence Comparing Benzalkonium Chloride-Preserved and Benzalkonium Chloride-Free Latanoprost in the Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension.
Journal: Clinical ophthalmology (Auckland, N.Z.)
Published: January 12, 2026
The effect of latanoprostene bunod on retinal vessel density in patients with primary open-angle glaucoma.
The effect of latanoprostene bunod on retinal vessel density in patients with primary open-angle glaucoma.
Journal: European journal of ophthalmology
Published: November 14, 2025
View All Latest Advances